explore -WSS

explore

author：leisure time 2025-10-01 21:34:56 - browse：35274

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Time to name cancers by genetics, not organ of origin, expert says

hotspot

focus

WSS

Vertigo drug brings hope for rare neuron disorder, Niemann

Some dementia cases could be undiagnosed liver disease

The effects of a landmark ruling on DNA ownership are becoming clearer

Welsh Carson private equity firm escapes from FTC antitrust case

Woodcock on FDA’s accelerated approval and her next chapter

Biden administration opens offers in Medicare drug price negotiations

Wikipedia

explore

explore

Jerome Adams on the need for new antivirals for Covid

Congressmen charge Covid hearing ‘could have been an email’

Jerome Adams on the need for new antivirals for Covid

Time to name cancers by genetics, not organ of origin, expert says

DIEP, the 'gold standard' of breast reconstruction, is under threat

New Ultima Genomics DNA sequencer can read genome for $100

Virginia high school admissions case could be legal follow

Woodcock on FDA’s accelerated approval and her next chapter

At least 13 dead in Texas as scorching temps continue

Lawmakers grill UnitedHealth CEO on Change cyberattack

focus

Has Bernie Sanders reached the limit of his pharma bullying effort?

GSK’s asthma push continues as drug succeeds in Phase 3 trials

HHS's proposed rule does nothing to address the climate crisis

Juul spent big to court Black leaders to promote its e

Cognito secures funding to test medical device for Alzheimer's

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

hotspot

focus

leisure time

hotspot